Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

TMDX

Live52w low +5.5%

Core line items from TMDX's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Entity: TransMedics Group, Inc.·Source: SEC EDGAR companyfacts

Metric	Q3 2022 2022-09-30	Q2 2022 2022-06-30	Q1 2022 2022-03-31	Annual 2021 2021-12-31
Revenue	$60.70M	$36.40M	$15.88M	$31.39M
Operating Income	$-24.66M	$-19.11M	$-9.37M	$-39.43M
Net Income	$-29.51M	$-11.52M	$-10.56M	$-44.22M
EPS (Diluted)	$-1.03	$-0.79	$-0.38	$-1.60
Total Assets	$274.87M	$117.28M	$124.01M	$134.89M
Total Liabilities	$87.02M	$66.37M	$64.10M	$67.04M
Cash & Equivalents	$204.46M	$30.39M	$17.90M	$25.58M
Free Cash Flow OCF − CapEx	$-50.92M	$-33.71M	$-20.36M	$-32.38M
Shares Outstanding	31.93M	28.02M	27.97M	27.79M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data.

Core line items from TMDX's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w low +5.5%

Entity: TransMedics Group, Inc.·Source: SEC EDGAR companyfacts

Metric	Q3 2022 2022-09-30	Q2 2022 2022-06-30	Q1 2022 2022-03-31	Annual 2021 2021-12-31
Revenue	$60.70M	$36.40M	$15.88M	$31.39M
Operating Income	$-24.66M	$-19.11M	$-9.37M	$-39.43M
Net Income	$-29.51M	$-11.52M	$-10.56M	$-44.22M
EPS (Diluted)	$-1.03	$-0.79	$-0.38	$-1.60
Total Assets	$274.87M	$117.28M	$124.01M	$134.89M
Total Liabilities	$87.02M	$66.37M	$64.10M	$67.04M
Cash & Equivalents	$204.46M	$30.39M	$17.90M	$25.58M
Free Cash Flow OCF − CapEx	$-50.92M	$-33.71M	$-20.36M	$-32.38M
Shares Outstanding	31.93M	28.02M	27.97M	27.79M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data.